Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C.

Clin Cancer Res. 2019 Jul 15;25(14):4320-4331. doi: 10.1158/1078-0432.CCR-18-1356. Epub 2019 Apr 23.

PMID:
31015344
2.

The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer.

Brunetto E, De Monte L, Balzano G, Camisa B, Laino V, Riba M, Heltai S, Bianchi M, Bordignon C, Falconi M, Bondanza A, Doglioni C, Protti MP.

J Immunother Cancer. 2019 Feb 13;7(1):45. doi: 10.1186/s40425-019-0521-4.

3.

Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.

Di Lullo G, Marcatti M, Heltai S, Tresoldi C, Paganoni AM, Bordignon C, Ciceri F, Protti MP.

Front Immunol. 2019 Jan 21;9:3171. doi: 10.3389/fimmu.2018.03171. eCollection 2018.

4.

Tumor-derived factors affecting immune cells.

Russo V, Protti MP.

Cytokine Growth Factor Rev. 2017 Aug;36:79-87. doi: 10.1016/j.cytogfr.2017.06.005. Epub 2017 Jun 8. Review.

PMID:
28606733
5.

T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F, Protti MP, Schumacher TN, Debets R, Swartz MA, Corti A, Bellone M, Mondino A.

Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

6.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.

7.

Non-redundant roles for Th17 and Th22 cells in multiple myeloma clinical correlates.

Di Lullo G, Marcatti M, Protti MP.

Oncoimmunology. 2015 Oct 29;5(4):e1093278. eCollection 2016 Apr.

8.

Quantitative and Qualitative Analysis of Tumor-Associated CD4⁺ T Cells.

Di Lullo G, De Monte L, Doglioni C, Protti MP.

Methods Mol Biol. 2016;1393:37-51. doi: 10.1007/978-1-4939-3338-9_4.

PMID:
27033214
9.

Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.

Wörmann SM, Song L, Ai J, Diakopoulos KN, Kurkowski MU, Görgülü K, Ruess D, Campbell A, Doglioni C, Jodrell D, Neesse A, Demir IE, Karpathaki AP, Barenboim M, Hagemann T, Rose-John S, Sansom O, Schmid RM, Protti MP, Lesina M, Algül H.

Gastroenterology. 2016 Jul;151(1):180-193.e12. doi: 10.1053/j.gastro.2016.03.010. Epub 2016 Mar 19.

PMID:
27003603
10.

Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients.

De Monte L, Wörmann S, Brunetto E, Heltai S, Magliacane G, Reni M, Paganoni AM, Recalde H, Mondino A, Falconi M, Aleotti F, Balzano G, Algül H, Doglioni C, Protti MP.

Cancer Res. 2016 Apr 1;76(7):1792-803. doi: 10.1158/0008-5472.CAN-15-1801-T. Epub 2016 Feb 12.

11.

Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.

Di Lullo G, Marcatti M, Heltai S, Brunetto E, Tresoldi C, Bondanza A, Bonini C, Ponzoni M, Tonon G, Ciceri F, Bordignon C, Protti MP.

Oncoimmunology. 2015 Feb 3;4(5):e1005460. eCollection 2015 May.

12.

Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.

Protti MP, De Monte L, Di Lullo G.

Tissue Antigens. 2014 Apr;83(4):237-46. doi: 10.1111/tan.12329. Review. Erratum in: Tissue Antigens. 2015 Jun;85(6):516. Monte, L D [corrected to De Monte, L]; Lullo, G D [corrected to Di Lullo, G].

PMID:
24641502
13.

Immune infiltrates as predictive markers of survival in pancreatic cancer patients.

Protti MP, De Monte L.

Front Physiol. 2013 Aug 9;4:210. doi: 10.3389/fphys.2013.00210. eCollection 2013.

14.

Estimating point and interval frequency of antigen-specific CD4+ T cells based on short in vitro expansion and improved poisson distribution analysis.

Di Lullo G, Ieva F, Longhi R, Paganoni AM, Protti MP.

PLoS One. 2012;7(8):e42340. doi: 10.1371/journal.pone.0042340. Epub 2012 Aug 7.

15.
16.

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP.

J Exp Med. 2011 Mar 14;208(3):469-78. doi: 10.1084/jem.20101876. Epub 2011 Feb 21.

17.

CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Seresini S, Origoni M, Caputo L, Lillo F, Longhi R, Vantini S, Paganoni AM, Protti MP.

Immunology. 2010 Sep;131(1):89-98. doi: 10.1111/j.1365-2567.2010.03277.x. Epub 2010 Jun 2.

18.

The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.

Cecconi V, Moro M, Del Mare S, Sidney J, Bachi A, Longhi R, Sette A, Protti MP, Dellabona P, Casorati G.

Eur J Immunol. 2010 Jun;40(6):1603-16. doi: 10.1002/eji.200940123.

19.

Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.

Tassi E, Braga M, Longhi R, Gavazzi F, Parmiani G, Di Carlo V, Protti MP.

PLoS One. 2009 Oct 2;4(10):e7234. doi: 10.1371/journal.pone.0007234.

20.

Carcinoembryonic antigen-specific but not antiviral CD4+ T cell immunity is impaired in pancreatic carcinoma patients.

Tassi E, Gavazzi F, Albarello L, Senyukov V, Longhi R, Dellabona P, Doglioni C, Braga M, Di Carlo V, Protti MP.

J Immunol. 2008 Nov 1;181(9):6595-603.

21.

Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells.

Marturano J, Longhi R, Russo V, Protti MP.

Cancer Res. 2008 Mar 1;68(5):1555-62. doi: 10.1158/0008-5472.CAN-07-5233.

22.

Serological immunoreactivity against colon cancer proteome varies upon disease progression.

De Monte L, Sanvito F, Olivieri S, Viganò F, Doglioni C, Frasson M, Braga M, Bachi A, Dellabona P, Protti MP, Alessio M.

J Proteome Res. 2008 Feb;7(2):504-14. doi: 10.1021/pr070360m. Epub 2008 Jan 8.

PMID:
18179166
23.

IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.

Seresini S, Origoni M, Lillo F, Caputo L, Paganoni AM, Vantini S, Longhi R, Taccagni G, Ferrari A, Doglioni C, Secchi P, Protti MP.

J Immunol. 2007 Nov 15;179(10):7176-83.

24.

MAGE-A3(161-175) contains an HLA-DRbeta4 restricted natural epitope poorly formed through indirect presentation by dendritic cells.

Marturano J, Longhi R, Casorati G, Protti MP.

Cancer Immunol Immunother. 2008 Feb;57(2):207-15. Epub 2007 Jul 13.

PMID:
17628799
25.

Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.

Tassi E, Facchinetti V, Seresini S, Borri A, Dell'antonio G, Garavaglia C, Casorati G, Protti MP.

Clin Cancer Res. 2006 Aug 15;12(16):4949-57.

26.

Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients.

Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP.

J Immunol. 2006 Apr 15;176(8):5093-9.

27.

Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.

Di Matteo P, Curnis F, Longhi R, Colombo G, Sacchi A, Crippa L, Protti MP, Ponzoni M, Toma S, Corti A.

Mol Immunol. 2006 Apr;43(10):1509-18. Epub 2005 Dec 7.

PMID:
16337683
28.

Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.

Moro M, Cecconi V, Martinoli C, Dallegno E, Giabbai B, Degano M, Glaichenhaus N, Protti MP, Dellabona P, Casorati G.

BMC Immunol. 2005 Dec 5;6:24.

29.

CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: identification of promiscuous naturally processed epitopes.

Facchinetti V, Seresini S, Longhi R, Garavaglia C, Casorati G, Protti MP.

Eur J Immunol. 2005 Mar;35(3):806-15.

30.

T-cell receptor-mediated cross-allergenicity.

Burastero SE, Paolucci C, Breda D, Longhi R, Silvestri M, Hammer J, Protti MP, Rossi GA.

Int Arch Allergy Immunol. 2004 Dec;135(4):296-305. Epub 2004 Nov 24.

PMID:
15583456
31.

Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice.

Feau S, Facchinetti V, Granucci F, Citterio S, Jarrossay D, Seresini S, Protti MP, Lanzavecchia A, Ricciardi-Castagnoli P.

Blood. 2005 Jan 15;105(2):697-702. Epub 2004 Sep 7.

PMID:
15353479
32.

CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope.

Campi G, Crosti M, Consogno G, Facchinetti V, Conti-Fine BM, Longhi R, Casorati G, Dellabona P, Protti MP.

Cancer Res. 2003 Dec 1;63(23):8481-6.

33.

Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3.

Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP.

Blood. 2003 Feb 1;101(3):1038-44. Epub 2002 Sep 19.

PMID:
12393675
34.

Cancer immunotherapy: synthetic and natural peptides in the balance.

Bellone M, Iezzi G, Imro MA, Protti MP.

Immunol Today. 1999 Oct;20(10):457-62. Review.

PMID:
10500293
35.

Role of antigen-presenting cells in cross-priming of cytotoxic T lymphocytes by apoptotic cells.

Ronchetti A, Iezzi G, Crosti MC, Garancini MP, Protti MP, Bellone M.

J Leukoc Biol. 1999 Aug;66(2):247-51.

PMID:
10449162
36.

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices.

Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J.

Nat Biotechnol. 1999 Jun;17(6):555-61.

PMID:
10385319
37.

Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines.

Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M.

J Immunol. 1999 Jul 1;163(1):130-6.

38.

Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).

Imro MA, Manici S, Russo V, Consogno G, Bellone M, Rugarli C, Traversari C, Protti MP.

Cancer Res. 1999 May 15;59(10):2287-91.

39.

Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytes.

Ferrarini M, Imro MA, Sciorati C, Heltai S, Protti MP, Pellicciari C, Rovere P, Manfredi AA, Rugarli C.

Int J Cancer. 1999 May 17;81(4):573-9.

40.

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP.

J Exp Med. 1999 Mar 1;189(5):871-6.

41.

Acetylcholine receptor-specific CD4+ T cells in myasthenia gravis patients have individual, but restricted TCR V beta usage.

Raju R, Navaneetham D, Protti MP, Horton RM, Hoppe BL, Howard J Jr, Conti-Fine BM.

Ann N Y Acad Sci. 1998 May 13;841:324-8. No abstract available.

PMID:
9668251
42.

Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro.

Imro MA, Dellabona P, Manici S, Heltai S, Consogno G, Bellone M, Rugarli C, Protti MP.

Hum Gene Ther. 1998 Jun 10;9(9):1335-44.

PMID:
9650618
43.

Processing of engulfed apoptotic bodies yields T cell epitopes.

Bellone M, Iezzi G, Rovere P, Galati G, Ronchetti A, Protti MP, Davoust J, Rugarli C, Manfredi AA.

J Immunol. 1997 Dec 1;159(11):5391-9.

PMID:
9548479
44.

Immunotherapy: natural versus synthetic peptides.

Protti MP, Bellone M.

Immunol Today. 1998 Feb;19(2):98. No abstract available.

PMID:
9509766
45.

The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes.

Iezzi G, Rivolta L, Ronchetti A, Martin-Fontecha A, Rosato A, Protti MP, Sabbadini MG, Bellone M.

Cancer Res. 1997 Jul 1;57(13):2564-8.

46.

TCR V beta usage by acetylcholine receptor-specific CD4+ T cells in myasthenia gravis.

Raju R, Navaneetham D, Protti MP, Horton RM, Hoppe BL, Howard J Jr, Conti-Fine BM.

J Autoimmun. 1997 Apr;10(2):203-17.

PMID:
9185882
47.

Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells.

Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C.

J Immunol. 1997 Jan 15;158(2):783-9.

PMID:
8992995
48.

Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro.

Protti MP, Imro MA, Manfredi AA, Consogno G, Heltai S, Arcelloni C, Bellone M, Dellabona P, Casorati G, Rugarli C.

Cancer Res. 1996 Mar 15;56(6):1210-3.

49.
50.

Immunoregulatory CD8+ cells recognize antigen-activated CD4+ cells in myasthenia gravis patients and in healthy controls.

Yuen MH, Protti MP, Diethelm-Okita B, Moiola L, Howard JF Jr, Conti-Fine BM.

J Immunol. 1995 Feb 1;154(3):1508-20.

PMID:
7529806

Supplemental Content

Loading ...
Support Center